-
Publication Venue For
-
Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis..
47:712-721.
2021
-
Electrocardiogram Characteristics and Their Association With Psychotropic Drugs Among Patients With Schizophrenia..
46:354-362.
2020
-
Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction..
44:286-296.
2018
-
Alternative Perspectives on Police Encounters and Psychotic Experiences [Invited Commentary on DeVylder et al, "Psychotic Experiences in the Context of Police Victimization"]..
43:946-948.
2017
-
Subthreshold Psychosis in 22q11.2 Deletion Syndrome: Multisite Naturalistic Study..
43:1079-1089.
2017
-
Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder..
43:397-406.
2017
-
The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms..
43:57-63.
2017
-
On Thoughts, Threats, and Throwing the Spear..
42:883-884.
2016
-
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia..
42:335-343.
2016
-
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia..
42:19-33.
2016
-
Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study..
41:1285-1293.
2015
-
Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study..
41:940-950.
2015
-
Visual hallucinations are associated with hyperconnectivity between the amygdala and visual cortex in people with a diagnosis of schizophrenia..
41:223-232.
2015
-
Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories..
40:1011-1021.
2014
-
Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis..
40:904-913.
2014
-
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data..
39:564-574.
2013
-
The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition..
39:583-591.
2013
-
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?.
39:417-435.
2013
-
Principal components of heritability from neurocognitive domains differ between families with schizophrenia and control subjects..
39:464-471.
2013
-
Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure..
38:1149-1154.
2012
-
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents..
38:153-166.
2012
-
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?.
37:1209-1217.
2011
-
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia..
37:1057-1065.
2011
-
A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians..
37:538-545.
2011
-
Methodological issues in negative symptom trials..
37:250-254.
2011
-
Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population..
37:94-100.
2011
-
Anticipating DSM-V: opportunities and challenges for cognition and psychosis..
36:43-47.
2010
-
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
2019